TORONTO, April 4 /CNW/ - ARIUS Research Inc. (TSX: ARI), a biotechnology
company discovering and developing the next wave of antibody therapeutics,
today announced that new information on the preclinical activity of two of its
novel monoclonal antibodies will be presented at the Annual Meeting of the
American Association for Cancer Research (AACR), which runs from April 14-18,
2007 in Los Angeles, California. The first poster presentation will outline
the activity of ARIUS' lead anti-CD44 antibody, ARH460-16-2, against liver
cancer, a significant market in Asia and a growing concern in North America.
CD44 is an important marker for cancer stem cells that often survive treatment
and keep growing to spread tumors. Studies of patients with different types of
cancer have shown that CD44 can be linked to poorer chances of survival. ARIUS
anti-CD44 antibodies have previously been found to control tumor growth and
improve survival in breast and prostate cancer models.
